HR 5237
117th Congress
House
Health
Accounting and auditing
Administrative law and regulatory procedures
Administrative remedies
Appropriations
Civil actions and liability
Competition and antitrust
Congressional oversight
Consumer affairs
Contracts and agency
Department of Health and Human Services
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Drug therapy
Federal Trade Commission (FTC)
Genetics
Government studies and investigations
Health care costs and insurance
Health care coverage and access
Health care quality
Reduced Costs and Continued Cures Act of 2021
Everywhere this bill has been
6 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 1, 2022
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Nov 1, 2022
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Sep 13, 2021
Referred to the Subcommittee on Health.
Sep 10, 2021
Introduced in House
Sep 10, 2021
Referred to the Subcommittee on Health.
Sep 10, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Reduced Costs and Continued Cures Act of 2021
This bill establishes and alters several programs and requirements relating to the prices of prescription drugs.
For example, the bill establishes and alters several requirements under Medicare and Medicaid, including
- requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation,
- capping annual out-of-pocket spending under the Medicare prescription drug benefit, and
- increasing the maximum rebate amount under the Medicaid Drug Rebate Program.
The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including
- authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics,
- limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and
- nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.
What's happening now
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Related & companion bills
10
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Cosponsors
4
Cite this page
U.S. Congress. (2026). H.R. 5237: Reduced Costs and Continued Cures Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-HR-5237/
"H.R. 5237: Reduced Costs and Continued Cures Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-5237/.
H.R. 5237, 117th Cong. (2026), https://openamerica.io/bill/117-HR-5237/.
[H.R. 5237: Reduced Costs and Continued Cures Act of 2021](https://openamerica.io/bill/117-HR-5237/)